2022
Clinical trials in multiple sclerosis: past, present, and future
Manouchehri N, Shirani A, Salinas VH, Tardo L, Hussain RZ, Pitt D, Stuve O. Clinical trials in multiple sclerosis: past, present, and future. Neurologia I Neurochirurgia Polska 2022, 56: 228-235. PMID: 35712986, DOI: 10.5603/pjnns.a2022.0041.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesMultiple sclerosisClinical trialsManagement of MSEffective disease-modifying therapiesDisability Assessment ScaleDisease-specific interventionsDisease diagnostic criteriaBurden of diseaseClinical trial developmentDisease-specific biomarkersMS pathophysiologyDiagnostic criteriaClinical practiceTrial developmentAssessment ScaleSclerosisTrialsPatientsNeuroimmunologyPathophysiologyTherapyDiseaseDiagnosisContinued progress
2017
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care
Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH, Gupta A, Tsiouris AJ, Kovanlikaya I, Chiang G, Weinsaft JW, Tanenbaum L, Chen W, Zhu W, Chang S, Lou M, Kopell BH, Kaplitt MG, Devos D, Hirai T, Huang X, Korogi Y, Shtilbans A, Jahng G, Pelletier D, Gauthier SA, Pitt D, Bush AI, Brittenham GM, Prince MR. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. Journal Of Magnetic Resonance Imaging 2017, 46: 951-971. PMID: 28295954, PMCID: PMC5592126, DOI: 10.1002/jmri.25693.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingQuantitative susceptibility mappingPatient careGradient-echo magnetic resonance imagingEcho magnetic resonance imagingAbnormal oxygen consumptionContrast agent injectionNormal cellular biochemistryMRI diagnosisPathologic processesMRI protocolResonance imagingAgent injectionBone mineralizationSpatial biodistributionGradient echo sequencePathologic calcificationJ. MagnTechnical efficacyDiseaseClinical applicationOxygen consumptionClinical translationMRI practiceImaging practices
2011
What happens when natalizumab therapy is stopped?
Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Review Of Neurotherapeutics 2011, 11: 1247-1250. PMID: 21864070, DOI: 10.1586/ern.11.109.Peer-Reviewed Original ResearchMS disease activityDisease activityActive diseaseNatalizumab cessationTreatment interruptionMultiple sclerosisBaseline levelsSimilar disease activityProgressive multifocal leukoencephalopathyNatalizumab exposureNatalizumab therapyNatalizumab treatmentMultifocal leukoencephalopathyMS patientsMRI measuresMS treatmentEvidence of reboundDiseaseElimination kineticsNatalizumabIntegrin antagonistsTreatmentPatientsCessationLeukoencephalopathy